Michaud GF, Stevenson WG. Atrial fibrillation. N Engl J Med. 2021;384(4):353-361.
Hindricks G, Potpara T, Dagres N. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. 2021;42(40):4194.
Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127(1):4-20.
Mou L, Norby FL, Chen LY. Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC Study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol. 2018;11(7):e006350.
January CT, Wann LS, Alpert JS. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-e76. 2014;64(21):2305-2307.
Cronin EM, Bogun FM, Maury P. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm. 2020;17(1):e2-e154.
Andrade JG, Aguilar M, Atzema C. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol. 2020;36(12):1847-1948.
Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of atrial fibrillation: a systematic review and meta-analysis of prospective studies. Eur J Prev Cardiol. 2018;25(13):1437-1451.
Heitmann KA, Løchen ML, Stylidis M, Hopstock LA, Schirmer H, Morseth B. Associations between physical activity, left atrial size and incident atrial fibrillation: the Tromsø Study 1994-2016. Open Heart. 2022;9(1):e001823.
- Elliott AD, Linz D, Verdicchio CV, Sanders P. Exercise and atrial fibrillation: prevention or causation? Heart Lung Circ. 2018;27(9):1078-1085.
Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the Cardiovascular Health Study. Circulation. 2008;118(8):800-807.
Goudis CA, Ntalas IV, Ketikoglou DG. Atrial fibrillation in athletes. Cardiol Rev. 2015;23(5):247-251.
Turagam MK, Velagapudi P, Kocheril AG. Atrial fibrillation in athletes. Am J Cardiol. 2012;109(2):296-302.
Lubitz SA, Yin X, Rienstra M. Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. Circulation. 2015;131(19):1648-1655.
Tisdale JE, Chung MK, Campbell KB. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation. 2020;142(15):e214-e233.
Davidson KW, Barry MJ, Mangione CM. Screening for atrial fibrillation: US Preventive Services Task Force recommendation statement. JAMA. 2022;327(4):360-367.
Boriani G, Laroche C, Diemberger I. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2015;128(5):509-18.e2.
Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol. 2013;168(5):4744-4749.
Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. Thromb Haemost. 2014;112(2):276-286.
- Mairesse GH, Moran P, Van Gelder IC. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). Europace. 2017;19(10):1589-1623. Erratum in Europace. 2018;20(4):658.
Turakhia MP, Desai M, Hedlin H. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study. Am Heart J. 2019;207:66-75.
Guo Y, Wang H, Zhang H. Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol. 2019;74(19):2365-2375.
Chen W, Khurshid S, Singer DE. Cost-effectiveness of screening for atrial fibrillation using wearable devices. JAMA Health Forum. 2022;3(8):e222419.
Marrouche NF, Brachmann J, Andresen D. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417-427.
Squizzato A, Luciani D, Rubboli A. Differential diagnosis of pulmonary embolism in outpatients with non-specific cardiopulmonary symptoms. Intern Emerg Med. 2013;8(8):695-702.
January CT, Wann LS, Calkins H. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151. 2019;140(6):e285.
Lan Q, Wu F, Han B, Ma L, Han J, Yao Y. Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: a meta-analysis. Am J Emerg Med. 2022;51:248-256.
Compagner CT, Wysocki CR, Reich EK, Zimmerman LH, Holzhausen JM. Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure. Am J Emerg Med. 2022;62:49-54.
Hasbrouck M, Nguyen TT. Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department. Am J Emerg Med. 2022;58:39-42.
Van Gelder IC, Hagens VE, Bosker HA. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-1840.
Wyse DG, Waldo AL, DiMarco JP. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.
Willems S, Borof K, Brandes A. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2022;43(12):1219-1230.
Um KJ, McIntyre WF, Healey JS. Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. Europace. 2019;21(6):856-863. 2019;21(6):863.
Reiffel JA, Capucci A. “Pill in the pocket” antiarrhythmic drugs for orally administered pharmacologic cardioversion of atrial fibrillation. Am J Cardiol. 2021;140:55-61.
Markman TM, Jarrah AA, Tian Y. Safety of pill-in-the-pocket Class 1C antiarrhythmic drugs for atrial fibrillation. JACC Clin Electrophysiol. 2022;8(12):1515-1520.
Peigh G, Passman RS. “Pill-in-pocket” anticoagulation for stroke prevention in atrial fibrillation. J Cardiovasc Electrophysiol. 2023;34(10):2152-2157.
- Passman R. “Pill-in-pocket” anticoagulation for atrial fibrillation: fiction, fact, or foolish? Circulation. 2021;143(23):2211-2213.
Calkins H, Hindricks G, Cappato R. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):e1-e160.
Packer DL, Mark DB, Robb RA. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261-1274.
Mao YJ, Feng WY, Huang QY, Yu FL, Chen JX, Wang H. Meta-analysis of cryoballoon ablation versus antiarrhythmic drugs as initial therapy for symptomatic atrial fibrillation. Clin Cardiol. 2021;44(10):1393-1401.
Patel M, Changal K, Patel N, Elzanaty A. Cryoablation versus antiarrhythmic therapy for initial treatment of atrial fibrillation: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2021;19(7):667-671.
Kheiri B, Simpson TF, Przybylowicz R. Ablation versus antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation: a meta-analysis of randomized trials. Circ Arrhythm Electrophysiol. 2021;14(8):e009692.
Harrison SL, Buckley BJR, Austin P, Lane DA, Lip GYH. Catheter ablation and lower risk of incident dementia and mortality in older adults with atrial fibrillation. J Am Geriatr Soc. 2023 :10.1111/jgs.18538.
Ganesan AN, Shipp NJ, Brooks AG. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(2):e004549.
Chew D, Piccini JP. Long-term oral anticoagulant after catheter ablation for atrial fibrillation. Europace. 2021;23(8):1157-1165.
Liu XH, Xu Q, Luo T, Zhang L, Liu HJ. Discontinuation of oral anti-coagulation therapy after successful atrial fibrillation ablation: a systematic review and meta-analysis of prospective studies. PLoS One. 2021;16(6):e0253709.
Verma A, Ha ACT, Kirchhof P. The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. Am Heart J. 2018;197:124-132.
Alsagaff MY, Susilo H, Pramudia C. Rapid atrial fibrillation in the emergency department. Heart Int. 2022;16(1):12-19.
Van Gelder IC, Groenveld HF, Crijns HJ. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-1373.
Diamant MJ, Andrade JG, Virani SA, Jhund PS, Petrie MC, Hawkins NM. Heart failure and atrial flutter: a systematic review of current knowledge and practices. ESC Heart Fail. 2021;8(6):4484-4496.
Brugada J, Katritsis DG, Arbelo E. 2019 ESC guidelines for the management of patients with supraventricular tachycardia: the Task Force for the Management of Patients With Supraventricular Tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720.
- Page RL, Joglar JA, Caldwell MA. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016;133(14):e506-e574. Erratum in Circulation. 2016;134(11):e234-e235.
Halligan SC, Gersh BJ, Brown RD. The natural history of lone atrial flutter. Ann Intern Med. 2004;140(4):265-268.
Cosío FG. Atrial flutter, typical and atypical: a review. Arrhythm Electrophysiol Rev. 2017;6(2):55-62.
Glover BM, Chen J, Hong KL. Catheter ablation for atrial flutter: a survey by the European heart rhythm association and Canadian Heart Rhythm Society. Europace. 2016;18(12):1880-1885.
Nunes-Ferreira A, Alves M, Lima da Silva G. Anticoagulation after typical atrial flutter ablation: systematic review and meta-analysis. Pacing Clin Electrophysiol. 2021;44(10):1701-1710.
- Sulzgruber P, Wassmann S, Semb AG. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. Eur Heart J Cardiovasc Pharmacother. 2019;5(3):171-180. Erratum in Eur Heart J Cardiovasc Pharmacother. 2020;6(5):309.
Zhu W, He W, Guo L. The HAS-BLED Score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2015;38(9):555-561.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.
Loewen P. SPARCtool—Stroke Prevention in Atrial Fibrillation Risk Tool. SPARCtool.com. https://www.sparctool.com/
Ganesan AN, Chew DP, Hartshorne T. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016;37(20):1591-1602.
Briosa E, Gala A, Pope MTB. ‘Pill-in-the-pocket’ oral anti-coagulation guided by daily rhythm monitoring for stroke prevention in patients with AF: a systematic review and meta-analysis. Arrhythm Electrophysiol Rev. 2023;12:e05.
Själander S, Själander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace. 2014;16(5):631-638.
Connolly S, Pogue J, Hart R. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-1912.
Clinical Key. Clinical Pharmacology. Stroke and systemic embolism prophylaxis in nonvalvular atrial fibrillation. https://www.clinicalkey.com/pharmacology/find-by/indication?termid=3460
Choi JH, Kim W, Kim YT. Cost-effectiveness of direct oral anticoagulant vs. warfarin among atrial fibrillation patients with intermediate stroke risk. Front Cardiovasc Med. 2022;9:849474.
Wu Y, Zhang C, Gu ZC. Cost-effectiveness analysis of direct oral anticoagulants vs. vitamin K antagonists in the elderly with atrial fibrillation: insights from the evidence in a real-world setting. Front Cardiovasc Med. 2021;8:675200.
Ruff CT, Giugliano RP, Braunwald E. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962.
Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2018(3):CD008980.
Lau WCY, Torre CO, Man KKC. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study. Ann Intern Med. 2022;175(11):1515-1524. 2023;176(1):144.
Turagam MK, Osmancik P, Neuzil P, Dukkipati SR, Reddy VY. Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials. J Am Coll Cardiol. 2020;76(23):2795-2797.
Ko D, Saleeba C, Sadiq H. Secondary precipitants of atrial fibrillation and anticoagulation therapy. J Am Heart Assoc. 2021;10(21):e021746.
- Jagadish PS, Kirolos I, Khare S, Rawal A, Lin V, Khouzam RN. Post-operative atrial fibrillation: should we anticoagulate? Ann Transl Med. 2019;7(17):407.
Greenberg JW, Lancaster TS, Schuessler RB. Postoperative atrial fibrillation following cardiac surgery: a persistent complication. Eur J Cardiothorac Surg. 2017;52(4):665-672.
Uittenbogaart SB, Lucassen WAM, van Etten-Jamaludin FS, de Groot JR, van Weert HCPM. Burden of atrial high-rate episodes and risk of stroke: a systematic review. Europace. 2018;20(9):1420-1427.
Gorenek B, Bax J, Boriani G. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2017;19(9):1556-1578.
Bertaglia E, Blank B, Blomström-Lundqvist C. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace. 2019;21(10):1459-1467.
Özge Mert G, Kepez A, Uğur Mert K, Görenek B. What to do with device-detected atrial high-rate episodes: summary of the evidences. Pacing Clin Electrophysiol. 2022;45(2):250-261.
Kirchhof P, Toennis T, Goette A. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med. 2023;389(13):1167-1179.
Lopes RD, Alings M, Connolly SJ. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J. 2017;189:137-145.
Otto CM, Nishimura RA, Bonow RO. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e35-e71.
Dawwas GK, Cuker A, Barnes GD, Lewis JD, Hennessy S. Apixaban versus rivaroxaban in patients with atrial fibrillation and valvular heart disease: a population-based study. Ann Intern Med. 2022;175(11):1506-1514.
Ryu R, Tran R. DOACs in mechanical and bioprosthetic heart valves: a narrative review of emerging data and future directions. Clin Appl Thromb Hemost. 2022;28:10760296221103578.
- Lau YC, Proietti M, Guiducci E, Blann AD, Lip GYH. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J Am Coll Cardiol. 2016;68(13):1452-1464. Erratum in J Am Coll Cardiol. 2016;68(25):2921.
Ha JT, Neuen BL, Cheng LP. Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2019;171(3):181-189.
Su X, Yan B, Wang L, Lv J, Cheng H, Chen Y. Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis. Am J Kidney Dis. 2021;78(5):678-689.e1.
Stanifer JW, Pokorney SD, Chertow GM. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141(17):1384-1392.
- Kuno T, Takagi H, Ando T. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol. 2020;75(3):273-285. Erratum in J Am Coll Cardiol. 2020;75(7):842.
Reinecke H, Engelbertz C, Bauersachs R. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 Study. Circulation. 2023;147(4):296-309.
Kumbhani DJ, Cannon CP, Beavers CJ. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(5):629-658.
Fohtung RB, Novak E, Rich MW. Effect of new oral anticoagulants on prescribing practices for atrial fibrillation in older adults. J Am Geriatr Soc. 2017;65(11):2405-2412.
Patti G, Lucerna M, Pecen L. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc. 2017;6(7):e005657.
Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J. 2018;39(6):453-460.
Deng K, Cheng J, Rao S, Xu H, Li L, Gao Y. Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis. Front Med (Lausanne). 2020;7:107.
Bonanad C, Formiga F, Anguita M, Petidier R, Gullón A. Oral anticoagulant use and appropriateness in elderly patients with atrial fibrillation in complex clinical conditions: ACONVENIENCE Study. J Clin Med. 2022;11(24):7423.
Polidori MC, Alves M, Bahat G. Atrial fibrillation: a geriatric perspective on the 2020 ESC guidelines. Eur Geriatr Med. 2022;13(1):5-18.
Allison R, Assadzandi S, Adelman M. Frailty: evaluation and management. Am Fam Physician. 2021;103(4):219-226.
Douketis JD, Spyropoulos AC, Murad MH. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest. 2022;162(5):e207-e243.
- Tomaselli GF, Mahaffey KW, Cuker A. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(5):594-622. Erratum in J Am Coll Cardiol. 2021;77(21):2760.
Steffel J, Verhamme P, Potpara TS. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-1393.
Delrue M, Chevillard L, Stépanian A. Case series of massive direct oral anticoagulant ingestion-treatment and pharmacokinetics data. Eur J Clin Invest. 2022;52(6):e13746.
Lin Y, Callum J. Emergency reversal of warfarin anticoagulation. CMAJ. 2010;182(18):2004.
Frontera JA, Bhatt P, Lalchan R. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. J Thromb Thrombolysis. 2020;49(1):121-131.
Müther M, Schwindt W, Mesters RM. Andexanet-alfa-associated heparin resistance in the context of hemorrhagic stroke. Neurocrit Care. 2022;37(2):372-376.
- Milling TJ, Pollack CV. A review of guidelines on anticoagulation reversal across different clinical scenarios—is there a general consensus? Am J Emerg Med. 2020;38(9):1890-1903.
Cohen AT, Lewis M, Connor A. Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding. J Am Coll Emerg Physicians Open. 2022;3(2):e12655.
PRAXBIND. PRAXBIND. Prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc; 2021.
Schiele F, van Ryn J, Canada K. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121(18):3554-3562.
- Crader MF, John T, Arnold JK. Warfarin drug interactions. StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK441964/
Khurshid S, Choi SH, Weng LC. Frequency of cardiac rhythm abnormalities in a half million adults. Circ Arrhythm Electrophysiol. 2018;11(7):e006273.
- Nattel S, Tomaselli GF. Mechanisms of cardiac arrhythmias. In: Libby P, Bonow RO, Mann DL, et al, eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Vol 2. 12th ed. Elsevier; 2022: 1163-1190.
- Marcus GM, Dewland TA. Premature atrial contractions: a wolf in sheep’s clothing? J Am Coll Cardiol. 2015;66(3):242-244.
Nguyen KT, Vittinghoff E, Dewland TA. Ectopy on a single 12-lead ECG, incident cardiac myopathy, and death in the community. J Am Heart Assoc. 2017;6(8):e006028.
Conen D, Adam M, Roche F. Premature atrial contractions in the general population: frequency and risk factors. Circulation. 2012;126(19):2302-2308.
Guichard JB, Guasch E, Roche F, Da Costa A, Mont L. Premature atrial contractions: a predictor of atrial fibrillation and a relevant marker of atrial cardiomyopathy. Front Physiol. 2022;13:971691.
Himmelreich JCL, Lucassen WAM, Heugen M. Frequent premature atrial contractions are associated with atrial fibrillation, brain ischaemia, and mortality: a systematic review and meta-analysis. Europace. 2019;21(5):698-707.
Huang BT, Huang FY, Peng Y. Relation of premature atrial complexes with stroke and death: systematic review and meta-analysis. Clin Cardiol. 2017;40(11):962-969.
Sasaki K, Nakajima I, Higuma T. Revisit to the prognostic value of premature atrial contraction burden in 24-h Holter electrocardiography for predicting undiagnosed atrial fibrillation—a propensity score-matched study. Circ J. 2021;85(8):1265-1272.
Gladstone DJ, Dorian P, Spring M. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. Stroke. 2015;46(4):936-941.
Dewland TA, Vittinghoff E, Mandyam MC. Atrial ectopy as a predictor of incident atrial fibrillation: a cohort study. Ann Intern Med. 2013;159(11):721-728.
García-Isla G, Mainardi L, Corino VDA. A detector for premature atrial and ventricular complexes. Front Physiol. 2021;12:678558.
Huang TC, Lee PT, Huang MS, Chiu PH, Su PF, Liu PY. The beneficial effects of beta blockers on the long-term prognosis of patients with premature atrial complexes. Front Cardiovasc Med. 2022;9:806743.
He B, Li Y, Huang W. Mapping and ablation of isolated frequent symptomatic premature atrial contractions in patients with structurally normal heart. Front Cardiovasc Med. 2022;9:862659.
Riesinger L, Siebermair J, Wakili R. Mapping strategies and ablation of premature atrial complexes. Herzschrittmacherther Elektrophysiol. 2021;32(1):9-13.
von Rotz M, Aeschbacher S, Bossard M. Risk factors for premature ventricular contractions in young and healthy adults. Heart. 2017;103(9):702-707.
Gorenek B, Fisher JD, Kudaiberdieva G. Premature ventricular complexes: diagnostic and therapeutic considerations in clinical practice: a state-of-the-art review by the American College of Cardiology Electrophysiology Council. J Interv Card Electrophysiol. 2020;57(1):5-26.
Sassone B, Muser D, Casella M. Detection of concealed structural heart disease by imaging in patients with apparently idiopathic premature ventricular complexes: a review of current literature. Clin Cardiol. 2019;42(12):1162-1169.
Latchamsetty R, Bogun F. Premature ventricular complex–induced cardiomyopathy. JACC Clin Electrophysiol. 2019;5(5):537-550.
Hosseini F, Thibert MJ, Gulsin GS. Cardiac magnetic resonance in the evaluation of patients with frequent premature ventricular complexes. JACC Clin Electrophysiol. 2022;8(9):1122-1132.
Suba S, Fleischmann KE, Schell-Chaple H. Diagnostic and prognostic significance of premature ventricular complexes in community and hospital-based participants: a scoping review. PLoS One. 2021;16(12):e0261712.
Sharma E, Arunachalam K, Di M, Chu A, Maan A. PVCs, PVC-induced cardiomyopathy, and the role of catheter ablation. Crit Pathw Cardiol. 2017;16(2):76-80.
Marcus GM. Evaluation and management of premature ventricular complexes. Circulation. 2020;141(17):1404-1418.
Arnar DO, Mairesse GH, Boriani G. Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). Europace. 2019;21(6):844-845.
Lee V, Perera D, Lambiase P. Prognostic significance of exercise-induced premature ventricular complexes: a systematic review and meta-analysis of observational studies. Heart Asia. 2017;9(1):14-24.
Klewer J, Springer J, Morshedzadeh J. Premature ventricular contractions (PVCs): a narrative review. Am J Med. 2022;135(11):1300-1305.
Loring Z, Hanna P, Pellegrini CN. Longer ambulatory ECG monitoring increases identification of clinically significant ectopy. Pacing Clin Electrophysiol. 2016;39(6):592-597.
- Napolitano C, Mazzanti A, Bloise R, Priori SG. Catecholaminergic polymorphic ventricular tachycardia. In: Adam MP, Mirzaa GM, Pagon RA, et al, eds. GeneReviews. University of Washington; 2023.
- Al-Khatib SM, Stevenson WG, Ackerman MJ. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):e91-e220. Erratum in J Am Coll Cardiol. 2018;72(14):1760.
Higuchi K, Bhargava M. Management of premature ventricular complexes. Heart. 2022;108(7):565-572.
Mahtani AU, Nair DG. Supraventricular tachycardia. Med Clin North Am. 2019;103(5):863-879.
Murer M, Cuculi F, Toggweiler S, Weberndoerfer V, Young M, Kobza R. Elevated high-sensitivity troponin does not indicate the presence of coronary artery disease in patients presenting with supraventricular tachycardia. Cardiol J. 2017;24(6):642-648.
- Kalman J, Sanders P. Supraventricular tachycardias. In: Libby P, Bonow RO, Mann DL, et al, eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Vol 2. 12th ed. Elsevier; 2022: 1245-1271.
Wang R, Blackburn G, Desai M. Accuracy of wrist-worn heart rate monitors. JAMA Cardiol. 2017;2(1):104-106.
Alzand BS, Crijns HJ. Diagnostic criteria of broad QRS complex tachycardia: decades of evolution. Europace. 2011;13(4):465-472.
Dobrzynski H, Boyett MR, Anderson RH. New insights into pacemaker activity: promoting understanding of sick sinus syndrome. Circulation. 2007;115(14):1921-1932.
John RM, Kumar S. Sinus node and atrial arrhythmias. Circulation. 2016;133(19):1892-1900.
- Patton KK, Olgin JE. Bradyarrhythmias and atrioventricular block. In: Libby P, Bonow RO, Mann DL, et al, eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Vol 2. 12th ed. Elsevier; 2022: 1312-1320.
Sathnur N, Ebin E, Benditt DG. Sinus node dysfunction. Card Electrophysiol Clin. 2021;13(4):641-659.
Jensen PN, Gronroos NN, Chen LY. Incidence of and risk factors for sick sinus syndrome in the general population. J Am Coll Cardiol. 2014;64(6):531-538.
Kusumoto FM, Schoenfeld MH, Barrett C. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140(8):e382-e482.
Mesirca P, Fedorov VV, Hund TJ. Pharmacologic approach to sinoatrial node dysfunction. Annu Rev Pharmacol Toxicol. 2021;61:757-778.
Chiabrando JG, Bonaventura A, Vecchié A. Management of acute and recurrent pericarditis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(1):76-92.
Lazarou E, Tsioufis P, Vlachopoulos C, Tsioufis C, Lazaros G. Acute pericarditis: update. Curr Cardiol Rep. 2022;24(8):905-913.
McNamara N, Ibrahim A, Satti Z, Ibrahim M, Kiernan TJ. Acute pericarditis: a review of current diagnostic and management guidelines. Future Cardiol. 2019;15(2):119-126.
Adler Y, Charron P, Imazio M. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-2964.
Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590.
Goddard K, Hanson KE, Lewis N. Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children and younger adults in the United States. Ann Intern Med. 2022;175(12):1169-1771.
Parmar K, Subramanyam S, Del Rio-Pertuz G. Cardiac adverse events after vaccination-a systematic review. Vaccines (Basel). 2022;10(5):700.
Bizzi E, Picchi C, Mastrangelo G, Imazio M, Brucato A. Recent advances in pericarditis. Eur J Intern Med. 2022;95:24-31.
Imazio M, Squarotti GB, Andreis A. Diagnostic and prognostic role of the electrocardiogram in patients with pericarditis. Heart. 2022;108(18):1474-1478.
Xu B, Kwon DH, Klein AL. Imaging of the pericardium. a multimodality cardiovascular imaging update. Cardiol Clin. 2017;35(4):491-503.
Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-715.
Sigvardt FL, Hansen ML, Kristensen SL. Risk factors for morbidity and mortality following hospitalization for pericarditis. J Am Coll Cardiol. 2020;76(22):2623-2631.
Imazio M, Brucato A, Cemin R. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-1528.
Pelliccia A, Sharma S, Gati S. 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17-96.
Pelliccia A, Solberg EE, Papadakis M. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2019;40(1):19-33.
Maron BJ, Udelson JE, Bonow RO. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132(22):e273-e280.
- Sivalokanathan S, Choksgi N. Pericarditis in athletes: approach to exercise restriction. American College of Cardiology; 2022. https://www.acc.org/latest-in-cardiology/articles/2022/09/06/11/53/pericarditis-in-athletes
- Roth GA, Mensah GA, Johnson CO. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. Erratum in J Am Coll Cardiol. 2021;77(15):1958-1959.
Gottlieb M, Bridwell R, Petrak V, Long B. Diagnosis and management of myocarditis: an evidence-based review for the emergency medicine clinician. J Emerg Med. 2021;61(3):222-233.
Harmon KG, Asif IM, Maleszewski JJ. Incidence, cause, and comparative frequency of sudden cardiac death in National Collegiate Athletic Association athletes: a decade in review. Circulation. 2015;132(1):10-19.
Ammirati E, Frigerio M, Adler ED. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail. 2020;13(11):e007405.
Piccirillo F, Watanabe M, Di Sciascio G. Diagnosis, treatment and predictors of prognosis of myocarditis. A narrative review. Cardiovasc Pathol. 2021;54:107362.
Olejniczak M, Schwartz M, Webber E, Shaffer A, Perry TE. Viral myocarditis-incidence, diagnosis and management. J Cardiothorac Vasc Anesth. 2020;34(6):1591-1601.
Lampejo T, Durkin SM, Bhatt N, Guttmann O. Acute myocarditis: aetiology, diagnosis and management. Clin Med (Lond). 2021;21(5):e505-e510.
Younis A, Matetzky S, Mulla W. Epidemiology characteristics and outcome of patients with clinically diagnosed acute myocarditis. Am J Med. 2020;133(4):492-499.
- Mahfoud F, Gärtner B, Kindermann M. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J. 2011;32(7):897-903.
Tymińska A, Ozierański K, Caforio ALP. Myocarditis and inflammatory cardiomyopathy in 2021: an update. Pol Arch Intern Med. 2021;131(6):594-606.
Caforio AL, Pankuweit S, Arbustini E. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-2648.
ACC/AHA Joint Committee members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. 2022;28(5):e1-e167.
Arfè A, Scotti L, Varas-Lorenzo C. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;354:i4857.
Cheng CY, Baritussio A, Giordani AS, Iliceto S, Marcolongo R, Caforio ALP. Myocarditis in systemic immune-mediated diseases: prevalence, characteristics and prognosis. a systematic review. Autoimmun Rev. 2022;21(4):103037.
Baritussio A, Schiavo A, Basso C. Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies. Eur J Heart Fail. 2022;24(6):1033-1044.
Castiello T, Georgiopoulos G, Finocchiaro G. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev. 2022;27(1):251-261.
Pepe S, Gregory AT, Denniss AR. Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination. Heart Lung Circ. 2021;30(10):1425-1429.
Gluckman TJ, Bhave NM, Allen LA. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;79(17):1717-1756.
Siripanthong B, Nazarian S, Muser D. Recognizing COVID-19–related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020;17(9):1463-1471.
Momtazmanesh S, Saeedi Moghaddam S, Malakan Rad E. Global, regional, and national burden and quality of care index of endocarditis: the global burden of disease study 1990-2019. Eur J Prev Cardiol. 2022;29(8):1287-1297.
Kitai T, Masumoto A, Okada T, Koyama T, Furukawa Y. Optimal timing of surgery for patients with active infective endocarditis. Cardiol Clin. 2021;39(2):197-209.
Rajani R, Klein JL. Infective endocarditis: a contemporary update. Clin Med (Lond). 2020;20(1):31-35.
- Baddour LM, Wilson WR, Bayer AS. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professional from the American Heart Association. Circulation. 2015;132(15):1435-1486. Errata in Circulation. 2015;132(17):e215; Circulation. 2016;134(8):e113; Circulation. 2018;138(5):e78-e79.
Philip J, Bond MC. Emergency considerations of infective endocarditis. Emerg Med Clin North Am. 2022;40(4):793-808.
Habib G, Lancellotti P, Antunes MJ. 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075-3128.
Wang A, Gaca JG, Chu VH. Management considerations in infective endocarditis. JAMA. 2018;320(1):72-83.
Bumm CV, Folwaczny M. Infective endocarditis and oral health—a narrative review. Cardiovasc Diagn Ther. 2021;11(6):1403-1415.
- Delgado V, Ajmone Marsan N, de Waha S. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042. Erratum in Eur Heart J. 2023;20:ehad625.
- Bruun NE, Habib G, Thuny F, Sogaard P. Cardiac imaging in infectious endocarditis. Eur Heart J. 2014;35(10):624-632. Erratum in Eur Heart J. 2014;35(34):2334.
Malik SB, Hsu JY, Hurwitz Koweek LM. ACR Appropriateness Criteria® infective endocarditis. J Am Coll Radiol. 2021;18(5S):S52-S61.
Roy SG, Akhtar T, Bandyopadhyay D. The emerging role of FDG PET/CT in diagnosing endocarditis and cardiac device infection. Curr Probl Cardiol. 2023;48(2):101510.
Habib G, Derumeaux G, Avierinos JF. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol. 1999;33(7):2023-2029.
- Tackling G, Lala V. Endocarditis antibiotic regimens. StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK542162/
Pries-Heje MM, Wiingaard C, Ihlemann N. Five-year outcomes of the Partial Oral Treatment of Endocarditis (POET) trial. N Engl J Med. 2022;386(6):601-602.
- Wilson WR, Gewitz M, Lockhart PB. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021;143(20):e963-e978. Errata in Circulation. 2021;144(9):e192; Circulation. 2022;145(17):e868.
